Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ATR-101

An orally bioavailable agent that is selective towards adrenal cortex cells with potential antitumor activity. Upon administration, ATR-101… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
CONTEXT Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic glucocorticoid doses to… Expand
2018
2018
BackgroundCushing’s syndrome in humans shares many similarities with its counterpart in dogs in terms of etiology (pituitary… Expand
  • table 1
  • table 2
  • figure 2
  • figure 1
  • table 3
2018
2018
Adrenocortical carcinoma (ACC) is a rare malignancy with a dismal outcome. Complete surgical resection remains the only… Expand
2017
2017
To further the development of new agents for the treatment of adrenocortical carcinoma (ACC), we characterized the molecular and… Expand
2016
2016
ATR-101 is a novel, oral drug candidate currently in development for the treatment of adrenocortical cancer. ATR-101 is a… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Adrenocortical carcinoma (ACC) generally has poor prognosis. Existing treatments provide limited benefit for most patients with… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2016
Review
2016
Adrenocortical carcinoma (ACC) is a malignancy that harbors a significant risk of recurrence even after complete resection and… Expand
2015
2015
TPS4585 Background: ATR-101 (Atterocor, Inc., Ann Arbor, MI, USA) is a selective inhibitor of ACAT1 (acyl coenzyme A:cholesterol… Expand
2015
2015
Cette invention concerne une nouvelle forme medicamenteuse solide du chlorhydrate de N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4… Expand